Original Article

Virchows Archiv

, Volume 462, Issue 1, pp 101-107

Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma

  • Hiroshi KitamuraAffiliated withDepartment of Urology, School of Medicine, Sapporo Medical University Email author 
  • , Toshihiko TorigoeAffiliated withDepartment of Pathology, School of Medicine, Sapporo Medical University
  • , Yoshihiko HirohashiAffiliated withDepartment of Pathology, School of Medicine, Sapporo Medical University
  • , Hiroko AsanumaAffiliated withDepartment of Pathology, School of Medicine, Sapporo Medical University
  • , Ryuta InoueAffiliated withDepartment of Urology, School of Medicine, Sapporo Medical University
  • , Sachiyo NishidaAffiliated withDepartment of Urology, School of Medicine, Sapporo Medical University
  • , Toshiaki TanakaAffiliated withDepartment of Urology, School of Medicine, Sapporo Medical University
  • , Naoya MasumoriAffiliated withDepartment of Urology, School of Medicine, Sapporo Medical University
  • , Noriyuki SatoAffiliated withDepartment of Pathology, School of Medicine, Sapporo Medical University
    • , Taiji TsukamotoAffiliated withDepartment of Urology, School of Medicine, Sapporo Medical University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Survivin, a member of the inhibitor of apoptosis protein gene family, inhibits apoptosis and promotes mitosis. We determined whether nuclear or cytoplasmic localization of survivin could predict survival of patients with upper urinary tract urothelial carcinoma (UUTUC). Immunohistochemical staining for survivin was carried out on archival specimens from 125 consecutive patients with UUTUC who underwent radical nephroureterectomy. Nuclear and cytoplasmic staining of survivin was scored and compared with clinicopathologic features and cancer-specific survival (CSS). Nuclear expression of survivin was significantly correlated with tumor grade (p < 0.001), lymphovascular invasion (p = 0.022) and poor survival with an estimated 5-year CSS probability of 54 % for tumors with nuclear expression of survivin vs. 73 % for those without nuclear expression of survivin (hazard ratio = 2.19; 95 % confidence interval = 1.02–4.70; p = 0.043). The 5-year cancer-specific survival rates of patients with cytoplasmic survivin-negative and -positive tumors were 66 and 67 %, respectively. There was no difference in survival between patients with cytoplasmic survivin-negative tumors and those with cytoplasmic survivin-positive tumors. Using univariate analysis, nuclear survivin expression, tumor grade, pathological T stage, pathological N stage, and lymphovascular invasion were the predictive variables for CSS. In contrast, cytoplasmic survivin expression had no prognostic relevance. These data suggest that nuclear accumulation of survivin represents biologic aggressiveness and that nuclear survivin is a negative prognostic marker in patients with resected UUTUC.

Keywords

Survivin Urothelial carcinoma Upper urinary tract Survival